NCT05104359View on ClinicalTrials.gov

COVID-19 Quantitative Antibody Titers & Booster Vaccinations

CompletedOBSERVATIONAL
Enrollment

825

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
COVID-19COVID-19 VaccinesImmunogenicity, Vaccine
Interventions
OTHER

Observational

HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.

Trial Locations (1)

10001

AHD Manhattan Midtown HCC, New York

Sponsors

Lead Sponsor

Epividian
All Listed Sponsors
collaborator

AIDS Healthcare Foundation

OTHER

lead

Epividian

INDUSTRY

NCT05104359 - COVID-19 Quantitative Antibody Titers & Booster Vaccinations | Biotech Hunter | Biotech Hunter